Background & Objective: Carcinoma is one of the main causes which lead to death. As the absence of tumor-antigen cross-presentation by professional antigen-presenting cells (APC), the interaction of naive T cells with neoplastic cells may lead to either tolerance or anergy. This is one of the reasons that block the T cell-mediated antitumor immunity. Dendritic cells (DC) are the most potent APC and stimulators of T cell activation. DC-mediated antitumor immunetherapy is an important part of antitumor therapy. It is mature DC but not immuature DC which can stimulate naive T cell. Cytokine can regulate the maturation of DC to enhance DCs ability in presenting antigen, and achieve the objective of activating the immune system. Therefore, investigating the factors that contribute to DC differentiation and maturation is necessary for the development of DC-mediated antitumor immunetherapy.LIGHT (for homologous to lymphotoxins, exhibits inducible expression , and competes with HSV glycoprotein D for HVEM, a receptor expressed by T lymphocytes), a recently identified cytokine, can regulate the molecular...
|